凉血化瘀方联合抗VEGF药物治疗湿性年龄相关性黄斑变性的临床观察  

Clinical observation on Liangxue Huayu formula combined with intravitreal injection of conbercept in treatment of wet age-related macular degeneration

作　　者：于磊[1] 秦虹[1] YU Lei;QIN Hong(Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)

机构地区：[1]中国中医科学院眼科医院,北京100040

出　　处：《中国中医眼科杂志》2020年第9期643-647,共5页China Journal of Chinese Ophthalmology

摘　　要：目的观察凉血化瘀方治疗湿性年龄相关性黄斑变性(AMD)的临床疗效。方法收集符合纳入标准的湿性AMD患者80例(80只眼),随机分成观察组40例(40只眼)和对照组40例(40只眼)。观察组予凉血化瘀方口服联合康柏西普注射液玻璃体腔注射;对照组予康柏西普注射液玻璃体腔注射;2组均经过康柏西普注射液玻璃体腔注射的负荷期治疗(每个月注射1次,连续注射3次)。分别于治疗后1个月、6个月、12个月检查患者的最佳矫正视力(BCVA)、视网膜中央厚度(CRT),并记录数据。统计12个月内黄斑水肿复发时间及玻璃体腔注药次数,对结果进行统计学分析。结果(1)BCVA:治疗后1个月,2组比较差异无统计学意义(t=-1.622,P=0.114)。治疗前后比较,观察组(t=11.297,P=0.000),对照组(t=12.524,P=0.000),差异均有统计学意义。治疗后6个月,2组比较差异有统计学意义(t=-2.134,P=0.040)。治疗前后比较,观察组(t=12.783,P=0.000),对照组(t=13.461,P=0.000),差异均有统计学意义。治疗后12个月,2组比较差异无统计学意义(t=-0.396,P=0.694)。治疗前后比较,观察组(t=12.974,P=0.000),对照组(t=13.496,P=0.000),差异均有统计学意义。(2)CRT:治疗后1个月,2组比较差异无统计学意义(t=-0.100,P=0.921)。治疗前后比较,观察组(t=11.227,P=0.000),对照组(t=12.576,P=0.000),差异均有统计学意义。治疗后6个月,2组比较差异有统计学意义(t=2.068,P=0.046)。治疗前后比较,观察组(t=-18.392,P=0.000),对照组(t=-17.917,P=0.000),差异均有统计学意义。治疗后12个月,2组比较差异无统计学意义(t=-0.094,P=0.926)。治疗前后比较,观察组(t=12.694,P=0.000),对照组(t=11.339,P=0.000),差异均有统计学意义。(3)黄斑水肿的平均复发时间:2组术后12个月内,观察组为(85.7±18.1)d,对照组为(53.7±12.3)d,2组比较差异有统计学意义(t=6.301,P=0.000)。(4)玻璃体腔注射次数:2组术后12个月内,观察组为(4.3±1.7)次,对照组为(6.7±2.1)次OBJECTIVE To observe the clinical effect of Liangxue Huayu Formula in the treatment of wet age-related macular degeneration(wAMD).METHODS A total of 80 patients(80 eyes)with wAMD were randomly divided into two groups:study group and control group according to different therapies.The study group was treated with Liangxue Huayu Formula combined with conbercept intravitreal injection(40 cases,40 eyes);The control group only received conbercept intravitreal injection(40cases,40 eyes).Both groups were treated by conbercept intravitreal injection in load dose(injected 3 times,once per month).The patients were followed up for 12 months.The number of lost cases in the 12-month follow-up period of the two groups:20 cases in observation group,22 cases in control group.The best corrected visual acuity(BCVA)and central retinal thickness(CRT)were examined at the 1st month,6 th month and 12 th month after treatment.The recurrence time of macular edema and the times of intravitreal injection in 12 months were counted.All the data were statistically analyzed.RESULTS(1)BCVA:One month after treatment,the difference between the two groups was not statistically significant(t=-1.622,P=0.114).Comparison within groups showed that the treatment group(t=11.297,P=0.000)and the control group(t=12.524,P=0.000)both experienced statistically significant variation.Six months after treatment,the difference between the two groups was statistically significant(t=-2.134,P=0.040).Comparison within groups showed that the treatment group(t=12.783,P=0.000)and the control group(t=13.461,P=0.000)both experienced statistically significant variation.Twelve months after treatment,the difference between the two groups was not statistically significant(t=-0.396,P=0.694).Comparison within groups showed that the treatment group(t=12.974,P=0.000)and the control group(t=13.496,P=0.000)both experienced statistically significant variation.(2)CRT:One month after treatment,the difference between the two groups was not statistically significant(t=-0.100,P=0.921).Comp

关 键 词：湿性年龄相关性性黄斑变性 凉血化瘀方 康柏西普注射液 

分 类 号：R246.82[医药卫生—针灸推拿学]